| abstract |
A glucagon and GLP-1 co-agonist compound useful in the treatment of type 2 diabetes, obesity, non-alcoholic steatohepatitis (NAFLD), and / or non-alcoholic steatohepatitis (NASH). A compound of the following formula or a pharmaceutically acceptable salt thereof: His-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu. -Lys-Lys-Ala-Lys-Glu-Phe-Val-Glu-Trp-Leu-Leu-Xaa28-Gly-Gly-Pro-Ser-Ser-Gly wherein Xaa2 is Aib and Xaa28 is Glu or Ser, Lys at position 20 has been chemically modified by a direct bond or via a linker between a ε-amino group in the side chain and a C14-C24 fatty acid, and the C-terminal amino acid is optionally amide Has been made]. [Selection diagram] None |